[Zurück]
 
Bitte auswählen
Jahr
Details
Sprache
Sortierung
Ausgabe
neu: RTF !
 Forschungsbericht für das Jahr 2017

Department Innere Medizin

Klinik für Innere Medizin I

Hugstetter Str. 55
79106 Freiburg
Tel: 0761/270-34060
https://www.uniklinik-freiburg.de/medizin1.html


Einträge in der Rubrik "Who is Who"

Wissenschaftliche Publikationen

Originalarbeiten in wissenschaftlichen Fachzeitschriften:
  • Andrlova H, Mastroianni J, Madl J, Kern JS, Melchinger W, Dierbach H, Wernet F, Follo M, Technau-Hafsi K, Has C, Rao Mittapalli V, Idzko M, Herr R, Brummer T, Ungefroren H, Busch H, Boerries M, Narr A, Ihorst G, Vennin C, Schmitt-Graeff A, Minguet S, Timpson P, Duyster J, Meiss F, Romer W, Zeiser R: Biglycan expression in the melanoma microenvironment promotes invasiveness via increased tissue stiffness inducing integrin-beta1 expression. Oncotarget, 2017; 8 (26): 42901-42916. : http://dx.doi.org/10.18632/oncotarget.17160
  • Brissot E, Labopin M, Stelljes M, Ehninger G, Schwerdtfeger R, Finke J, Kolb HJ, Ganser A, Schafer-Eckart K, Zander AR, Bunjes D, Mielke S, Bethge WA, Milpied N, Kalhs P, Blau IW, Kroger N, Vitek A, Gramatzki M, Holler E, Schmid C, Esteve J, Mohty M, Nagler A: Comparison of matched sibling donors versus unrelated donors in allogeneic stem cell transplantation for primary refractory acute myeloid leukemia: a study on behalf of the Acute Leukemia Working Party of the EBMT. J Hematol Oncol, 2017; 10 (1): 130-130. : http://dx.doi.org/10.1186/s13045-017-0498-8
  • Czulkies BA, Mastroianni J, Lutz L, Lang S, Schwan C, Schmidt G, Lassmann S, Zeiser R, Aktories K, Papatheodorou P: Loss of LSR affects epithelial barrier integrity and tumor xenograft growth of Oncotarget, 2017; 8 (23): 37009-37022. : http://dx.doi.org/10.18632/oncotarget.10425
  • de Witte T, Bowen D, Robin M, Malcovati L, Niederwieser D, Yakoub-Agha I, Mufti GJ, Fenaux P, Sanz G, Martino R, Alessandrino EP, Onida F, Symeonidis A, Passweg J, Kobbe G, Ganser A, Platzbecker U, Finke J, van Gelder M, van de Loosdrecht AA, Ljungman P, Stauder R, Volin L, Deeg HJ, Cutler C, Saber W, Champlin R, Giralt S, Anasetti C, Kroger N: Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel. Blood, 2017; 129 (13): 1753-1762. : http://dx.doi.org/10.1182/blood-2016-06-724500
  • Duque-Afonso J, Waterhouse M, Pfeifer D, Follo M, Duyster J, Bertz H, Finke J: Cell-free DNA characteristics and chimerism analysis in patients after allogeneic cell transplantation. Clin Biochem, 2017. : http://dx.doi.org/10.1016/j.clinbiochem.2017.11.015 (in Druck)
  • Eder S, Beohou E, Labopin M, Sanz J, Finke J, Arcese W, Or R, Bonifazi F, Aljurf M, Socie G, Passweg J, Giebel S, Mohty M, Nagler A: Thiotepa-based conditioning for allogeneic stem cell transplantation in acute lymphoblastic leukemia-A survey from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Am J Hematol, 2017; 92 (1): 18-22. : http://dx.doi.org/10.1002/ajh.24567
  • Eder S, Canaani J, Beohou E, Labopin M, Sanz J, Arcese W, Or R, Finke J, Cortelezzi A, Beelen D, Passweg J, Socie G, Gurman G, Aljurf M, Stelljes M, Giebel S, Mohty M, Nagler A: Thiotepa-based conditioning versus total body irradiation as myeloablative conditioning prior to allogeneic stem cell transplantation for acute lymphoblastic leukemia: A matched-pair analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Am J Hematol, 2017; 92 (10): 997-1003. : http://dx.doi.org/10.1002/ajh.24823
  • Eder S, Labopin M, Finke J, Bunjes D, Olivieri A, Santarone S, Rambaldi A, Kanz L, Messina G, Mohty M, Nagler A: Safety and efficacy of thiotepa-based conditioning for allogeneic transplantation in AML: a survey from the ALWP of the EBMT. Bone Marrow Transpl, 2017; 52 (2): 238-244. : http://dx.doi.org/10.1038/bmt.2016.239
  • Engelhardt M, Domm AS, Dold SM, Ihorst G, Reinhardt H, Zober A, Hieke S, Baayen C, Muller SJ, Einsele H, Sonneveld P, Landgren O, Schumacher M, Wasch R: A concise revised Myeloma Comorbidity Index as a valid prognostic instrument in a large cohort of 801 multiple myeloma patients. Haematologica, 2017; 102 (5): 910-921. : http://dx.doi.org/10.3324/haematol.2016.162693
  • Engelhardt M, Selder R, Pandurevic M, Moller M, Ihorst G, Waldschmidt J, Herget G, Wasch R: [Multidisciplinary Tumor Boards: Facts and Satisfaction Analysis of an Indispensable Comprehensive Cancer Center Instrument]. Deut Med Wochenschr, 2017; 142 (9): e51-e60. : http://dx.doi.org/10.1055/s-0043-100054
  • Ferreri AJM, Cwynarski K, Pulczynski E, Fox CP, Schorb E, La Rosee P, Binder M, Fabbri A, Torri V, Minacapelli E, Falautano M, Ilariucci F, Ambrosetti A, Roth A, Hemmaway C, Johnson P, Linton KM, Pukrop T, Sonderskov Gorlov J, Balzarotti M, Hess G, Keller U, Stilgenbauer S, Panse J, Tucci A, Orsucci L, Pisani F, Levis A, Krause SW, Schmoll HJ, Hertenstein B, Rummel M, Smith J, Pfreundschuh M, Cabras G, Angrilli F, Ponzoni M, Deckert M, Politi LS, Finke J, Reni M, Cavalli F, Zucca E, Illerhaus G: Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial. Lancet Haematol, 2017; 4 (11) (online): e510-e523. : http://dx.doi.org/10.1016/S2352-3026(17)30174-6
  • Finke J, Schmoor C, Bethge WA, Ottinger H, Stelljes M, Volin L, Heim D, Bertz H, Grishina O, Socie G: Long-term outcomes after standard graft-versus-host disease prophylaxis with or without anti-human-T-lymphocyte immunoglobulin in haemopoietic cell transplantation from matched unrelated donors: final results of a randomised controlled trial. Lancet Haematol, 2017; 4 (6): e293-e301. : http://dx.doi.org/10.1016/S2352-3026(17)30081-9
  • Fritsch K, Kasenda B, Schorb E, Hau P, Bloehdorn J, Mohle R, Low S, Binder M, Atta J, Keller U, Wolf HH, Krause SW, Hess G, Naumann R, Sasse S, Hirt C, Lamprecht M, Martens U, Morgner A, Panse J, Frickhofen N, Roth A, Hader C, Deckert M, Fricker H, Ihorst G, Finke J, Illerhaus G: High-dose methotrexate-based immuno-chemotherapy for elderly primary CNS lymphoma patients (PRIMAIN study). Leukemia, 2017; 31 (4): 846-852. : http://dx.doi.org/10.1038/leu.2016.334
  • Gay F, Engelhardt M, Terpos E, Wasch R, Giaccone L, Auner HW, Caers J, Gramatzki M, van de Donk N, Oliva S, Zamagni E, Garderet L, Straka C, Hajek R, Ludwig H, Einsele H, Dimopoulos M, Boccadoro M, Kroger N, Cavo M, Goldschmidt H, Bruno B, Sonneveld P: From transplant to novel cellular therapies in multiple myeloma: EMN guidelines and future perspectives. Haematologica, 2017. : http://dx.doi.org/10.3324/haematol.2017.174573 (in Druck)
  • Gerboth S, Frittoli E, Palamidessi A, Baltanas FC, Salek M, Rappsilber J, Giuliani C, Troglio F, Rolland Y, Pruneri G, Kreutmair S, Pallavicini I, Zobel M, Cinquanta M, Minucci S, Gomez C, Santos E, Illert AL, Scita G: Phosphorylation of SOS1 on tyrosine 1196 promotes its RAC GEF activity and contributes to BCR-ABL leukemogenesis. Leukemia, 2017. : http://dx.doi.org/10.1038/leu.2017.267 (in Druck)
  • Greil C, Ihorst G, Gaiser F, Salzer U, Bisse E, Kastritis E, Ludwig H, Wasch R, Engelhardt M: The serum heavy/light chain immunoassay: A valuable tool for sensitive paraprotein assessment, risk, and disease monitoring in monoclonal gammopathies. Eur J Haematol, 2017; 99 (5): 449-458. : http://dx.doi.org/10.1111/ejh.12958
  • Greil C, Ihorst G, Kiote-Schmidt C, Hildenbeutel S, Kuhbach K, Bosse R, Duyster J, Engelhardt M, Wasch R: Stem cell mobilization in poor mobilizers with multiple myeloma or lymphoma before and after introduction of plerixafor: a single-center comparative analysis using a cost-efficient single fixed-dose schedule. Leukemia Lymphoma, 2017: 1-4. : http://dx.doi.org/10.1080/10428194.2017.1393673 (in Druck)
  • Greil C, Kiote-Schmidt C, Fink G, Ihorst G, Hildenbeutel S, Bosse R, Duyster J, Engelhardt M, Wasch R: Successful peripheral blood stem cell mobilization with a cost-efficient single fixed-dose plerixafor schedule in poor mobilizers. Leukemia Lymphoma, 2017; 58 (8): 1849-1858. : http://dx.doi.org/10.1080/10428194.2016.1271946
  • Heidenreich S, Ziagkos D, de Wreede LC, van Biezen A, Finke J, Platzbecker U, Niederwieser D, Einsele H, Bethge W, Schleuning M, Beelen DW, Tischer J, Nagler A, Glass B, Maertens J, Yanez L, Beguin Y, Sill H, Scheid C, Stelljes M, Ganser A, Zachee P, Selleslag D, de Witte T, Robin M, Kroger N: Allogeneic Stem Cell Transplantation for Patients Age >/= 70 Years with Myelodysplastic Syndrome: A Retrospective Study of the MDS Subcommittee of the Chronic Malignancies Working Party of the EBMT. Biol Blood Marrow Tr, 2017; 23 (1): 44-52. : http://dx.doi.org/10.1016/j.bbmt.2016.09.027
  • Heiland DH, Demerath T, Kellner E, Kiselev VG, Pfeifer D, Schnell O, Staszewski O, Urbach H, Weyerbrock A, Mader I: Molecular differences between cerebral blood volume and vessel size in glioblastoma multiforme. Oncotarget, 2017; 8 (7): 11083-11093. : http://dx.doi.org/10.18632/oncotarget.11522
  • Heiland DH, Haaker G, Delev D, Mercas B, Masalha W, Heynckes S, Gabelein A, Pfeifer D, Carro MS, Weyerbrock A, Prinz M, Schnell O: Comprehensive analysis of PD-L1 expression in glioblastoma multiforme. Oncotarget, 2017; 8 (26): 42214-42225. : http://dx.doi.org/10.18632/oncotarget.15031
  • Heiland DH, Simon-Gabriel CP, Demerath T, Haaker G, Pfeifer D, Kellner E, Kiselev VG, Staszewski O, Urbach H, Weyerbrock A, Mader I: Integrative Diffusion-Weighted Imaging and Radiogenomic Network Analysis of Glioblastoma multiforme. Sci Rep-uk, 2017; 7: 43523-43523. : http://dx.doi.org/10.1038/srep43523
  • Heiland DH, Worner J, Gerrit Haaker J, Delev D, Pompe N, Mercas B, Franco P, Gabelein A, Heynckes S, Pfeifer D, Weber S, Mader I, Schnell O: The integrative metabolomic-transcriptomic landscape of glioblastome multiforme. Oncotarget, 2017; 8 (30): 49178-49190. : http://dx.doi.org/10.18632/oncotarget.16544
  • Hettmer S, Andrieux G, Hochrein J, Kurz P, Rossler J, Lassmann S, Werner M, von Bubnoff N, Peters C, Koscielniak E, Sparber-Sauer M, Niemeyer C, Mentzel T, Busch H, Boerries M: Epithelioid hemangioendotheliomas of the liver and lung in children and adolescents. Pediatr Blood Cancer, 2017; 64 (12) (online). : http://dx.doi.org/10.1002/pbc.26675
  • Hiller JK, Schmoor C, Gaidzik VI, Schmidt-Salzmann C, Yalcin A, Abdelkarim M, Blagitko-Dorfs N, Dohner K, Bullinger L, Duyster J, Lubbert M, Hackanson B: Evaluating the impact of genetic and epigenetic aberrations on survival and response in acute myeloid leukemia patients receiving epigenetic therapy. Ann Hematol, 2017; 96 (4): 559-565. : http://dx.doi.org/10.1007/s00277-016-2912-7
  • Kamasani S, Akula S, Sivan SK, Manga V, Duyster J, Vudem DR, Kancha RK: Computational analysis of ABL kinase mutations allows predicting drug sensitivity against selective kinase inhibitors. Tumor Biol, 2017; 39 (5) (online): 1010428317701643-1010428317701643. : http://dx.doi.org/10.1177/1010428317701643
  • Kasenda B, Ihorst G, Schroers R, Korfel A, Schmidt-Wolf I, Egerer G, von Baumgarten L, Roth A, Bloehdorn J, Mohle R, Binder M, Keller U, Lamprecht M, Pfreundschuh M, Valk E, Fricker H, Schorb E, Fritsch K, Finke J, Illerhaus G: High-dose chemotherapy with autologous haematopoietic stem cell support for relapsed or refractory primary CNS lymphoma: a prospective multicentre trial by the German Cooperative PCNSL study group. Leukemia, 2017; 31 (12): 2623-2629. : http://dx.doi.org/10.1038/leu.2017.170
  • Kobitzsch B, Gokbuget N, Schwartz S, Reinhardt R, Bruggemann M, Viardot A, Wasch R, Starck M, Thiel E, Hoelzer D, Burmeister T: Loss-of-function but not dominant-negative intragenic IKZF1 deletions are associated with an adverse prognosis in adult BCR-ABL-negative acute lymphoblastic leukemia. Haematologica, 2017; 102 (10): 1739-1747. : http://dx.doi.org/10.3324/haematol.2016.161273
  • Krafft C, Wilhelm K, Eremin A, Nestel S, von Bubnoff N, Schultze-Seemann W, Popp J, Nazarenko I: A specific spectral signature of serum and plasma-derived extracellular vesicles for cancer screening. Nanomed-nanotechnol, 2017; 13 (3): 835-841. : http://dx.doi.org/10.1016/j.nano.2016.11.016
  • Martino R, Henseler A, van Lint M, Schaap N, Finke J, Beelen D, Vigouroux S, Alessandrino EP, Mufti GJ, Veelken JH, Bruno B, Yakoub-Agha I, Volin L, Maertens J, Or R, Leblond V, Rovira M, Kalhs P, Alvarez AF, Vitek A, Sierra J, Wagner E, Robin M, de Witte T, Kroger N: Long-term follow-up of a retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic transplantation from matched related donors in myelodysplastic syndromes. Bone Marrow Transpl, 2017; 52 (8): 1107-1112. : http://dx.doi.org/10.1038/bmt.2017.19
  • Meissner J, Finel H, Dietrich S, Boumendil A, Kanfer E, Laboure G, Abecasis M, Cornelissen J, Delage J, Finke J, Hess U, Ludwig H, Mohty M, Pabst T, Pioltelli P, Robinson S, Samaras P, Montoto S, Dreger P: Autologous hematopoietic stem cell transplantation for intravascular large B-cell lymphoma: the European Society for Blood and Marrow Transplantation experience. Bone Marrow Transpl, 2017; 52 (4): 650-652. : http://dx.doi.org/10.1038/bmt.2016.339
  • Onida F, de Wreede LC, van Biezen A, Eikema DJ, Byrne JL, Iori AP, Schots R, Jungova A, Schetelig J, Finke J, Veelken H, Johansson JE, Craddock C, Stelljes M, Theobald M, Holler E, Schanz U, Schaap N, Bittenbring J, Olavarria E, Chalandon Y, Kroger N: Allogeneic stem cell transplantation in patients with atypical chronic myeloid leukaemia: a retrospective study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation. Brit J Haematol, 2017; 177 (5): 759-765. : http://dx.doi.org/10.1111/bjh.14619
  • Pastor V, Hirabayashi S, Karow A, Wehrle J, Kozyra EJ, Nienhold R, Ruzaike G, Lebrecht D, Yoshimi A, Niewisch M, Ripperger T, Gohring G, Baumann I, Schwarz S, Strahm B, Flotho C, Skoda RC, Niemeyer CM, Wlodarski MW: Mutational landscape in children with myelodysplastic syndromes is distinct from adults: specific somatic drivers and novel germline variants. Leukemia, 2017; 31 (3): 759-762. : http://dx.doi.org/10.1038/leu.2016.342
  • Pavlu J, Labopin M, Zoellner AK, Sakellari I, Stelljes M, Finke J, Fanin R, Stuhler G, Afanasyev BV, Bloor AJ, Anagnostopoulos A, Mohty M, Giebel S, Nagler A: Allogeneic hematopoietic cell transplantation for primary refractory acute lymphoblastic leukemia: A report from the Acute Leukemia Working Party of the EBMT. Cancer Cytopathol, 2017; 123 (11): 1965-1970. : http://dx.doi.org/10.1002/cncr.30604
  • Peschel I, Podmirseg SR, Taschler M, Duyster J, Gotze KS, Sill H, Nachbaur D, Jakel H, Hengst L: FLT3 and FLT3-ITD phosphorylate and inactivate the cyclin-dependent kinase inhibitor p27(Kip1) in acute myeloid leukemia. Haematologica, 2017; 102 (8): 1378-1389. : http://dx.doi.org/10.3324/haematol.2016.160101
  • Qi W, Yan Y, Pfeifer D, Donner V Gromoff E, Wang Y, Maier W, Baumeister R: C. elegans DAF-16/FOXO interacts with TGF-ss/BMP signaling to induce germline tumor formation via mTORC1 activation. Plos Genet, 2017; 13 (5) (online): e1006801-e1006801. : http://dx.doi.org/10.1371/journal.pgen.1006801
  • Rassner MP, Seidl M, Salzer U, Rajkumar SV, Epting T, Wasch R, Neumann-Haefelin E, Engelhardt M: Cast Nephropathy and Deceptively Low Absolute Serum Free Light Chain Levels: Resolution of a Challenging Case and Systematic Review of the Literature. Clin Lymphoma Myeloma Leuk, 2017. : http://dx.doi.org/10.1016/j.clml.2017.09.019 (in Druck)
  • Reinhardt H, Trittler R, Eggleton AG, Wohrl S, Epting T, Buck M, Kaiser S, Jonas D, Duyster J, Jung M, Hug MJ, Engelhardt M: Paving the Way for Dose Banding of Chemotherapy: An Analytical Approach. J Natl Compr Canc Ne, 2017; 15 (4): 484-493.
  • Rubel F, Kern JS, Technau-Hafsi K, Uhrich S, Thoma K, Hacker G, von Bubnoff N, Meiss F, von Bubnoff D: Indoleamine 2,3-dioxygenase expression in primary cutaneous melanoma correlates with Breslow thickness and is of significant prognostic value for progression-free survival. J Invest Dermatol, 2017. : http://dx.doi.org/10.1016/j.jid.2017.09.036 (in Druck)
  • Rugo HS, Barve A, Waller CF, Hernandez-Bronchud M, Herson J, Yuan J, Sharma R, Baczkowski M, Kothekar M, Loganathan S, Manikhas A, Bondarenko I, Mukhametshina G, Nemsadze G, Parra JD, Abesamis-Tiambeng ML, Baramidze K, Akewanlop C, Vynnychenko I, Sriuranpong V, Mamillapalli G, Ray S, Yanez Ruiz EP, Pennella E: Effect of a Proposed Trastuzumab Biosimilar Compared With Trastuzumab on Overall Response Rate in Patients With ERBB2 (HER2)-Positive Metastatic Breast Cancer: A Randomized Clinical Trial. Jama-j Am Med Assoc, 2017; 317 (1): 37-47. : http://dx.doi.org/10.1001/jama.2016.18305
  • Schnerch D, Schuler J, Follo M, Felthaus J, Wider D, Klingner K, Greil C, Duyster J, Engelhardt M, Wasch R: Proteasome inhibition enhances the efficacy of volasertib-induced mitotic arrest in AML in vitro and prolongs survival in vivo. Oncotarget, 2017; 8 (13): 21153-21166. : http://dx.doi.org/10.18632/oncotarget.15503
  • Schorb E, Fox CP, Fritsch K, Isbell L, Neubauer A, Tzalavras A, Witherall R, Choquet S, Kuittinen O, De-Silva D, Cwynarski K, Houillier C, Hoang-Xuan K, Touitou V, Cassoux N, Marolleau JP, Tamburini J, Houot R, Delwail V, Illerhaus G, Soussain C, Kasenda B: High-dose thiotepa-based chemotherapy with autologous stem cell support in elderly patients with primary central nervous system lymphoma: a European retrospective study. Bone Marrow Transpl, 2017; 52 (8): 1113-1119. : http://dx.doi.org/10.1038/bmt.2017.23
  • Simon-Gabriel CP, Foerster K, Saleem S, Bleckmann D, Benkisser-Petersen M, Thornton N, Umezawa K, Decker S, Burger M, Veelken H, Claus R, Dierks C, Duyster J, Zirlik K: The microenvironmental stromal cells abrogate NF-kappaB inhibitor induced apoptosis in chronic lymphocytic leukemia. Haematologica, 2017. : http://dx.doi.org/10.3324/haematol.2017.165381
  • Stickel N, Hanke K, Marschner D, Prinz G, Kohler M, Melchinger W, Pfeifer D, Schmitt-Graeff A, Brummer T, Heine A, Brossart P, Wolf D, von Bubnoff N, Finke J, Duyster J, Ferrara J, Salzer U, Zeiser R: MicroRNA-146a reduces MHC-II expression via targeting JAK/STAT signaling in dendritic cells after stem cell transplantation. Leukemia, 2017; 31 (12): 2732-2741. : http://dx.doi.org/10.1038/leu.2017.137
  • Strassburg S, Nabar N, Lampert F, Goerke SM, Pfeifer D, Finkenzeller G, Stark GB, Simunovic F: Calmodulin Regulated Spectrin Associated Protein 1 mRNA is Directly Regulated by miR-126 in Primary Human Osteoblasts. J Cell Biochem, 2017; 118 (7): 1756-1763. : http://dx.doi.org/10.1002/jcb.25838
  • Strussmann T, Fritsch K, Baumgarten A, Fietz T, Engelhardt M, Mertelsmann R, Ihorst G, Duyster J, Finke J, Marks R: Favourable outcomes of poor prognosis diffuse large B-cell lymphoma patients treated with dose-dense Rituximab, high-dose Methotrexate and six cycles of Brit J Haematol, 2017; 178 (6): 927-935. : http://dx.doi.org/10.1111/bjh.14802
  • von Bubnoff N: Liquid Biopsy: Approaches to Dynamic Genotyping in Cancer. Oncol Res Treat, 2017; 40 (7-8): 409-416. : http://dx.doi.org/10.1159/000478864
  • Waldschmidt JM, Simon A, Wider D, Muller SJ, Follo M, Ihorst G, Decker S, Lorenz J, Chatterjee M, Azab AK, Duyster J, Wasch R, Engelhardt M: CXCL12 and CXCR7 are relevant targets to reverse cell adhesion-mediated drug resistance in multiple myeloma. Brit J Haematol, 2017; 179 (1): 36-49. : http://dx.doi.org/10.1111/bjh.14807
  • Waterhouse M, Pfeifer D, Follo M, Duyster J, Schafer H, Bertz H, Finke J: Early mixed hematopoietic chimerism detection by digital droplet PCR in patients undergoing gender-mismatched hematopoietic stem cell transplantation. Clin Chem Lab Med, 2017; 55 (8): 1115-1121. : http://dx.doi.org/10.1515/cclm-2016-0900
  • Weinberg F, Reischmann N, Fauth L, Taromi S, Mastroianni J, Kohler M, Halbach S, Becker AC, Deng N, Schmitz T, Uhl FM, Herbener N, Riedel B, Beier F, Swarbrick A, Lassmann S, Dengjel J, Zeiser R, Brummer T: The Atypical Kinase RIOK1 Promotes Tumor Growth and Invasive Behavior. EBioMedicine, 2017; 20: 79-97. : http://dx.doi.org/10.1016/j.ebiom.2017.04.015
  • Yalcin A, Kovarbasic M, Wehrle J, Claus R, Becker H, Abdelkarim M, Gaidzik VI, Schmidts A, Wasch R, Pahl HL, Dohner K, Bullinger L, Duyster J, Lubbert M, Hackanson B: The oligodendrocyte lineage transcription factor 2 (OLIG2) is epigenetically regulated in acute myeloid leukemia. Exp Hematol, 2017; 55: 76-85.e3. : http://dx.doi.org/10.1016/j.exphem.2017.07.009
  • Zeiser R, Negrin RS: Introduction to a review series on chronic GVHD: from pathogenic B-cell receptor signaling to novel therapeutic targets. Blood, 2017; 129 (1): 1-2. : http://dx.doi.org/10.1182/blood-2016-10-735696

Besondere wissenschaftliche Aktivitäten

Preise / Ehrungen:
  • Dr. Verena Klämbt: Albrecht-Fleckenstein-Preis, für Ihre Promotionsarbeit (AG Zeiser), 22.08.2016.

Abschlussarbeiten

Promotionen
  • Bach, Annika: Vergleichende Analyse von Therapie und prognostischen Faktoren zwischen transformiertem Follikulärem Lymphom,transformierer Chronisch Lymphatischer Leukämie und rezidiviertem Diffusgroßzelligen B-Zell-Lymphom (Betreuer/in PD Dr. Reinhard Marks, Erstgutachter/in PD Dr. Reinhard Marks, Zweitgutachter/in Prof. Dr. Klaus Warnatz), 2017.
  • Fassbender, Fanny: Immunhistologische Untersuchungen bei Arthrofibrose des Kniegelenks (Erstgutachter/in Prof. Dr. Monika Engelhardt, Zweitgutachter/in Prof. Dr. Hermann Mayr), 2017.
  • Hartmann, David: Der Hedgehog-Signaleweg in Non-Hodgkin-Lymphomen (Erstgutachter/in PD Dr. Christine Dierks, Zweitgutachter/in Dr. Miriam Erlacher), 2017.
  • Nango, Lea: Analyse zirkulierender Tumorzellen beim Lungenkarzinom (Erstgutachter/in Prof. Dr. Monika Engelhardt, Zweitgutachter/in Prof. Dr. Hermann Mayr), 2017.
  • Reinhardt, Heike: Schrittweise Implementierung von Dose Banding bei der onkologischen Chemotherapie mit Hilfe analytischer Methoden und Fehlerassessment bei hochkomplexen Chemotherapien zur Optimierung der Arzneimittelsicherheit und Wirtschaftlichkeit (Erstgutachter/in Prof. Dr. Monika Engelhardt, Zweitgutachter/in Prof. Dr. Hermann Mayr), 2017.
  • Schmidt, Cornelius: Kinasen als therapeutisches Target in der CLL und ihr Einfluss auf das Mikromilieu (Erstgutachter/in PD Dr. Christine Dierks, Zweitgutachter/in Prof. Dr. Katja E. Odening), 2017.
  • Selder, Ricarda: Das interdisziplinäre Tumorboard (TB) 'Multiples Myelom' des Comprehensive Cancer Center Freiburg (CCCF): Analyse von Patientencharakteristika, Vorstellungshäufigkeit, Fragestellungen an die Konferenz, Patientenoutcome und Befolgungsgrad der TB-Empfehlungen (Erstgutachter/in Prof. Dr. Monika Engelhardt, Zweitgutachter/in Prof. Dr. Hermann Mayr), 2017.